A dose of hope: CT1812 from Cognition proves its ability in Alzheimer’s Aβ…
Cognition Therapeutics Inc CGTX announces the publication of data from a Phase 1b SNAP study of CT1812 measuring Aβ oligomer displacement in Alzheimer’s disease Journal
Home » CT1812
Cognition Therapeutics Inc CGTX announces the publication of data from a Phase 1b SNAP study of CT1812 measuring Aβ oligomer displacement in Alzheimer’s disease Journal
The three hours after midnight are, by a wide margin, the most dangerous time to be on the road in Charlotte, according to a new
Nursing home residents who report abuse are often met with retaliation rather than protection, according to a new report from The Schiller Kessler Group examining
Every successful business strives to increase productivity while maintaining healthy profitability. Although market conditions, competition, and customer demands continue to evolve, organizations that adopt smart